DJIA 16,643.01 -11.76 -0.07%
NASDAQ 4,828.33 15.62 0.32%
S&P 500 1,988.87 1.21 0.06%
market minute promo

Rexahn Pharmaceuticals (NYSEMKT: RNN)

0.55 0.01 (2.56%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

RNN $0.55 2.56%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $0.54
Previous Close $0.54
Daily Range $0.53 - $0.55
52-Week Range $0.50 - $0.96
Market Cap $99.2M
P/E Ratio -7.64
Dividend (Yield) $0.00 (0.0%)
Volume 242,925
Average Daily Volume 320,700
Current FY EPS -$0.10

Sector

Healthcare

Industry

Drug Makers

Rexahn Pharmaceuticals (RNN) Description

Rexahn Pharmaceuticals Inc. is a clinical stage biopharmaceutical company developing and seeking to deliver novel cures for cancer and disorders of the central nervous system (CNS) to patients worldwide. Website: http://www.rexahn.com/

News & Commentary Rss Feed

This Week in Biotech: NW Bio Soars While Geron Goes Geronimo

Two early-stage study results, a rare hospital exemption approval in Germany, and a devastating full clinical hold for one biotech are among this week's top biotech stories.

Tuesday Sector Leaders: Oil & Gas Exploration & Production, Biotechnology Stocks

Rexahn Pharmaceuticals Awarded Patent in Japan for Novel Targeted Cancer Drug Delivery Platform

Data on Rexahn's RX-3117 in Non-Small Cell Lung Cancer Presented at 16th International Symposium of

Data on Rexahn's RX-3117 in Non-Small Cell Lung Cancer Presented at 16th International Symposium of the Purine and Pyrimidine Society

Rexahn Pharmaceuticals to Present Data on RX-3117 & Supinoxin at the 2015 American Association for C

Rexahn Pharmaceuticals to Present Data on RX-3117 & Supinoxin at the 2015 American Association for Cancer Research Annual Meeting

Rexahn Pharmaceuticals: One Biotech To Buy For A Catalyst-Filled 2015

UPDATE: MLV & Co Initiates Coverage On Rexahn Pharmaceuticals On Oncology Pipeline With Strategic Fl

UPDATE: MLV & Co Initiates Coverage On Rexahn Pharmaceuticals On Oncology Pipeline With Strategic Flexibility

Onxeo: An Upcoming Mid-Sized Pharma With Ambitions

Rexahn's Lead Drug RX-3117 Beats Lilly's Gemzar In One-To-One Face Off

Rexahn Pharmaceuticals (RNN) Jumps: Stock Rises 12.5% - Tale of the Tape

Can The Uptrend Continue for Rexahn Pharmaceuticals (RNN)? - Tale of the Tape

See More RNN News...

RNN's Top Competitors

RNN $0.55 (2.56%)
Current stock: RNN
AMGN $155.89 (0.11%)
Current stock: AMGN
GILD $107.78 (-0.19%)
Current stock: GILD
BIIB $303.69 (-0.26%)
Current stock: BIIB